By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its proprietary HER2-targeted antibody-drug conjugate (ADC), trastuzumab rezetecan (SHR-A1811), has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE) for use in combination with pertuzumab in treatment-naïve patients with HER2-positive recurrent or metastatic breast cancer. This marks the molecule’s third major regulatory recognition in China and its first in a first-line metastatic setting.
Regulatory & Clinical Context
| Status | Detail |
|---|---|
| New BTD Indication | HER2+ recurrent/metastatic breast cancer, no prior anti-HER2 therapy |
| Regimen | Trastuzumab rezetecan + pertuzumab (dual HER2 blockade + cytotoxic payload) |
| Existing Approvals in China | 1. HER2-mutant NSCLC (post–≥1 systemic therapy) 2. HER2+ metastatic breast cancer (post–≥1 anti-HER2 regimen) |
| Molecule Type | In-house developed HER2-targeted ADC with proprietary linker-payload technology |
HER2-positive breast cancer accounts for 15–20% of all breast cancers in China, with significant unmet need in the first-line metastatic setting where current standards rely on trastuzumab/pertuzumab/docetaxel—a regimen limited by toxicity and resistance.
Strategic Implications
- Market Expansion: The BTD accelerates potential approval in the highest-value patient segment—newly diagnosed metastatic cases—positioning SHR-A1811 as a backbone therapy
- Differentiation: Unlike traditional HER2 antibodies, the ADC delivers a cytotoxic payload directly to tumor cells, potentially improving depth and duration of response
- Competitive Landscape: Competes with Enhertu (trastuzumab deruxtecan), but offers a domestically developed, potentially lower-cost alternative with strong CDE support
- Global Potential: Data from this combination could support future FDA or EMA filings, especially given Enhertu’s global dominance
Hengrui is also evaluating trastuzumab rezetecan in gastric cancer, colorectal cancer, and other HER2-expressing solid tumors, leveraging its modular ADC platform.
Financial & Pipeline Outlook
With two commercial indications already launched in China and now a breakthrough-tagged first-line breast cancer study, SHR-A1811 is poised to become one of Hengrui’s top revenue drivers by 2028. Analysts estimate peak annual sales exceeding ¥5 billion (~US$700 million) across all indications if first-line approval is secured.
Forward‑Looking Statements
This brief contains forward-looking information regarding regulatory designations, clinical development, and commercial potential. Actual outcomes may differ due to trial results, competitive dynamics, and reimbursement decisions.-Fineline Info & Tech